DR. SOLIMAN ABDEL KADER
FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

For the three-month and nine-month periods ended
30 September 2026
together with the
INDEPENDENT AUDITORS' REVIEW REPORT

DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
For the nine-month period ended 30 September 2026

Index	**Page**
Independent auditor's report on review of condensed consolidated interim financial statements	1
Condensed consolidated interim statement of financial position	2
Condensed consolidated interim statement of profit or loss and other comprehensive income	3
Condensed consolidated interim statement of changes in equity	4
Condensed consolidated interim statement of cash flows	5 – 6
Notes to the condensed consolidated interim financial statements	7 – 30

ERNST & YOUNG PROFESSIONAL SERVICES (PROFESSIONAL LLC)
Paid-Up Capital (SR 5,500,000 - Five Million Five Hundred Thousand Saudi Riyal)
King's Road Tower, 13th Floor
King Abdul Aziz Road (Malek Road)
P.O. Box 1994 - Jeddah 21441
Kingdom of Saudi Arabia
Head Office - Riyadh - C.R. No. 1010383821

C.R. No. 4030276644
Tel: +966 12 221 8400
Fax: +966 12 664 4408
ey.ksa@sa.ey.com
www.ey.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

To the Shareholders of Dr. Soliman Abdel Kader Fakeeh Hospital Company (A Saudi Joint Stock Company)

Introduction

We have reviewed the accompanying condensed consolidated interim statement of financial position of Dr. Soliman Abdel Kader Fakeeh Hospital Company (the "Company") and its subsidiaries (collectively referred to as the "Group") as at 30 September 2026, and the related condensed consolidated interim statement of profit or loss and other comprehensive income for the three-month and nine-month periods ended 30 September 2026, and the related condensed consolidated interim statements of changes in equity and cash flows for the nine-month period then ended, and explanatory notes. Management is responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with the International Accounting Standard 34, *"Interim Financial Reporting"* ("IAS 34") as endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these condensed consolidated interim financial statements based on our review.

Scope of Review

We conducted our review in accordance with the International Standard on Review Engagements 2410, *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, as endorsed in the Kingdom of Saudi Arabia. A review of interim financial statement consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements are not prepared, in all material respects, in accordance with IAS 34 as endorsed in the Kingdom of Saudi Arabia.

for Ernst & Young Professional Services

Ahmed Ibrahim Reda
Certified Public Accountant
License No. 356

Jeddah: 11 November 2026G
1 Jumada Al-Akhirah 1448H

DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION
As at 30 September 2026
(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

	Notes	30 September 2026 (Unaudited)	31 December 2025 (Audited)
ASSETS			
Property and equipment	5	**3,644,079**	2,498,755
Right-of-use assets "RoU"	6.1	**591,751**	492,247
Goodwill and intangible assets	7	**1,587,285**	547,568
Investment properties		**345**	376
Financial asset at amortized cost		**--**	298,126
Prepayments and other non-current assets		**24,013**	22,244
Investment in an associate	8	**70,082**	--
Other long-term receivables	9	**135,950**	144,748
Non-current assets		**6,053,505**	4,004,064
Inventories		**224,628**	196,293
Accounts receivables	10	**1,228,374**	974,978
Contract assets		**45,019**	39,798
Prepayments and other current assets		**191,119**	174,382
Financial asset at amortized cost – Current portion		**300,275**	--
Cash and cash equivalents	11	**436,372**	439,162
Current assets		**2,425,787**	1,824,613
Total assets		**8,479,292**	5,828,677
EQUITY AND LIABILITIES			
EQUITY			
Share capital	12	**232,000**	232,000
Treasury shares	12.a	**(2,000)**	(2,000)
Share premium		**1,653,473**	1,653,473
Retained earnings		**1,351,257**	1,288,560
Equity attributable to shareholders of the Company		**3,234,730**	3,172,033
Non-controlling interests ("NCI")		**413,919**	409,353
Total equity		**3,648,649**	3,581,386
LIABILITIES			
Long-term loans	13	**2,324,476**	334,000
Lease liabilities	6.2	**573,567**	481,162
Employees' end of service benefits		**347,956**	312,996
Non-current liabilities		**3,245,999**	1,128,158
Short-term loans	13	**609,006**	297,543
Current portion of long-term loans	13	**43,700**	--
Current portion of lease liabilities	6.2	**80,900**	63,662
Accounts payables		**373,674**	362,234
Accrued and other current liabilities		**459,592**	365,403
Provision for Zakat	14	**17,772**	30,291
Current liabilities		**1,584,644**	1,119,133
Total liabilities		**4,830,643**	2,247,291
Total equity and liabilities		**8,479,292**	5,828,677

Mr. Ammar Faqih	Dr. Mazen Fakeeh	Mr. Taha Bin Shaukat
Chairman Board of Directors	President	Group Chief Financial Officer

The accompanying notes 1 to 25 form an integral part of these condensed consolidated interim financial statements.

DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
For the three-month and nine-month periods ended 30 September 2026
(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

	Notes	For the three-month period ended 30 September		For the nine-month period ended 30 September	
		2026	2025	**2026**	2025
		(Unaudited)	(Unaudited)	**(Unaudited)**	(Unaudited)
Revenue	15	**931,263**	778,259	**2,454,319**	2,291,121
Costs of revenue		**(729,368)**	(601,013)	**(1,937,551)**	(1,757,123)
Gross profit		**201,895**	177,246	**516,768**	533,998
Other income		**4,101**	3,863	**11,130**	10,882
Selling and marketing expenses		**(22,075)**	(20,619)	**(61,134)**	(57,646)
General and administrative expenses	16	**(104,148)**	(80,577)	**(259,626)**	(235,293)
Impairment loss on accounts receivables	10.1	**(9,325)**	(5,786)	**(22,375)**	(19,223)
Operating profit		**70,448**	74,127	**184,763**	232,718
Finance costs	17.a	**(35,455)**	(14,100)	**(69,120)**	(34,040)
Finance income	17.b	**7,212**	4,729	**20,644**	17,863
Share of profit from investment in an associate	8	**82**	--	**82**	--
Profit before zakat		**42,287**	64,756	**136,369**	216,541
Zakat	14	**(4,357)**	(7,645)	**(18,133)**	(23,914)
Profit for the period		**37,930**	57,111	**118,236**	192,627
Other comprehensive income:					
Items that will not be reclassified to profit or loss:					
Re-measurement income on defined benefit obligations		--	--	--	--
Total comprehensive income for the period		**37,930**	57,111	**118,236**	192,627
Profit / (loss) for the period attributable to:					
- Shareholders of the Parent Company		**38,747**	71,643	**135,090**	225,966
- Non-controlling interests		**(817)**	(14,532)	**(16,854)**	(33,339)
		37,930	57,111	**118,236**	192,627
Total comprehensive income / (loss) for the period attributable to:					
- Shareholders of the Parent Company		**38,747**	71,643	**135,090**	225,966
- Non-controlling interests		**(817)**	(14,532)	**(16,854)**	(33,339)
		37,930	57,111	**118,236**	192,627
Earnings per share					
Basic and diluted earnings per share	18	**0.17**	0.31	**0.59**	0.98

Mr. Ammar Faqih	Dr. Mazen Fakeeh	Mr. Taha Bin Shaukat
Chairman Board of Directors	President	Group Chief Financial Officer

The accompanying notes 1 to 25 form an integral part of these condensed consolidated interim financial statements.

DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY
For the nine-month period ended 30 September 2026
(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

	Attributed to shareholders of the Parent Company						
	Share capital	Treasury shares	Share premium	Retained earnings	Total	Non-controlling interests	Total equity
Balance at 1 January 2025 (Audited)	**232,000**	**(2,000)**	**1,653,473**	**1,061,873**	**2,945,346**	**374,078**	**3,319,424**
Total comprehensive income for the period							
Profit / (loss) for the period	--	--	--	225,966	225,966	(33,339)	192,627
Employee share-based payments reserve charged to profit and loss	--	--	--	5,668	5,668	--	5,668
Transactions with shareholders							
Dividend declared (note 12)	--	--	--	(69,000)	(69,000)	--	(69,000)
Additional capital contribution by NCI	--	--	--	--	--	69,879	69,879
Balance at 30 September 2025 (Unaudited)	232,000	(2,000)	1,653,473	1,224,507	3,107,980	410,618	3,518,598
Balance at 1 January 2026 (Audited)	**232,000**	**(2,000)**	**1,653,473**	**1,288,560**	**3,172,033**	**409,353**	**3,581,386**
Total comprehensive income for the period							
Profit / (loss) for the period	--	--	--	135,090	135,090	(16,854)	118,236
Employee share-based payments reserve charged to profit and loss	--	--	--	3,507	3,507	--	3,507
Transactions with shareholders							
Dividend declared (note 12)	--	--	--	(75,900)	(75,900)	--	(75,900)
Additional capital contribution by NCI	--	--	--	--	--	21,420	21,420
Balance at 30 September 2026 (Unaudited)	**232,000**	**(2,000)**	**1,653,473**	**1,351,257**	**3,234,730**	**413,919**	**3,648,649**

Mr. Ammar Faqih	Dr. Mazen Fakeeh	Mr. Taha Bin Shaukat
Chairman Board of Directors	President	Group Chief Financial Officer

The accompanying notes 1 to 25 form an integral part of these condensed consolidated interim financial statements.

DR. SOLIMAN ABDEL KADER FAKEEH HOSPITAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS
For the nine-month period ended 30 September 2026
(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

	Notes	**For the nine-month period ended 30 September 2026 (Unaudited)**	For the nine-month period ended 30 September 2025 (Unaudited)
Cash flows from operating activities			
Profit before Zakat		**136,369**	216,541
Adjustments to reconcile profit before Zakat to net cash flows:			
- Depreciation on property and equipment	5.1	**108,313**	85,146
- Depreciation on right-of-use assets	6.1	**51,901**	46,121
- Amortization of intangible assets		**8,225**	5,581
- Depreciation on investment properties		**31**	30
- Share of profit from an associate	8	**(82)**	--
- Provision for employee's end of service benefits		**42,120**	42,938
- Impairment loss on accounts receivables	10.1	**22,375**	19,223
- Gain on disposal of property and equipment and RoU		**(115)**	(1,917)
- Non-Cash Share based Payment plan expense	16, 12.a	**3,507**	5,668
- Discounting impact of DAAM scholarship program		**1,201**	967
- Net finance costs		**48,476**	16,177
		422,321	436,475
Changes in operating assets and liabilities:			
- Inventories		**(12,057)**	(26,910)
- Accounts receivables		**(152,417)**	(151,308)
- Contract assets		**(5,221)**	(9,885)
- Other long-term receivables		**7,597**	(29,260)
- Prepayments and other current assets		**(1,253)**	12,913
- Accounts payables		**(60,507)**	10,398
- Accrued and other current liabilities		**94,831**	133,454
Cash generated from operating activities		**293,294**	375,877
Finance cost paid		**(41,068)**	(27,073)
Finance cost paid on lease	6.2	**(28,694)**	(23,400)
Employees' end of service benefits paid		**(26,864)**	(11,233)
Zakat paid	14	**(31,946)**	(27,512)
Net cash generated from operating activities		**164,722**	286,659
Cash flows from investing activities:			
Additions to property and equipment	5.1	**(226,426)**	(422,553)
Additions to intangible assets		**(4,272)**	(3,877)
Investment in an associate	8	**(70,000)**	--
Prepayments and other non-current assets		**(1,769)**	722
Interest received		**18,495**	17,456
Proceeds from disposal of property and equipment		**4,656**	(667)
Acquisition of a new subsidiary, net of cash acquired		**(1,575,815)**	--
Net cash used in investing activities		**(1,855,131)**	(408,919)
Cash flows from financing activities:			
Additional capital contribution by NCI		**21,420**	69,879
Repayment of principal portion of lease liability	6.2	**(42,431)**	(35,040)
Proceeds from long-term loans		**1,802,000**	12,500
Repayment of long-term loans		**(328,933)**	--
Dividend paid	12	**(75,900)**	(69,000)
Net movement in short term loans		**311,463**	2,011
Net cash generated from/(used in) financing activities		**1,687,619**	(19,650)
Net decrease in cash and cash equivalents		**(2,790)**	(141,910)
Cash and cash equivalents at beginning of the period		**439,162**	533,785
Cash and cash equivalents at the end of the period	11	**436,372**	391,875

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS (continued)
For nine-month period ended 30 September 2026
(All Amounts expressed in thousands of Saudi Riyals, unless otherwise stated)

	Notes	**For the nine-month period ended 30 September 2026 (Unaudited)**	For the nine-month period ended 30 September 2025 (Unaudited)
Significant non-cash transactions:			
Addition to right-of-use assets and lease liabilities	6.2	**138,958**	26,125

Mr. Ammar Faqih	Dr. Mazen Fakeeh	Mr. Taha Bin Shaukat
Chairman Board of Directors	President	Group Chief Financial Officer

The accompanying notes 1 to 25 form an integral part of these condensed consolidated interim financial statements.

1. GENERAL

Dr. Soliman Abdel Kader Fakeeh Hospital Company (the "Parent Company") is a Saudi Joint Stock Company formed under the laws of the Kingdom of Saudi Arabia and is registered in the Commercial Registry in Jeddah under No. 4030014511 and Unified Identification Number 7001713341 on 11 Rabi II 1398H (20 March 1978). The Parent Company shares were listed on the Tadawul Primary Market, commencing trading under the symbol 4017 and ISIN code SA562GSHUOH7.

These condensed consolidated interim financial statements include assets, liabilities and the results of the operations of the Parent Company and its following subsidiaries collectively referred to as "the Group". The condensed interim financial statements of the subsidiaries are prepared for the same reporting period and using consistent accounting policies as that of the Parent Company.

The Group's registered office and principal place of business is Jeddah.

The principal activity of the Group is managing, establishing and operating hospitals, clinics, medical, educational and training centers. In addition to the above, the Group is also managing and operating medical services, analysis and radiology laboratory and managing and establishing pharmacies, wholesale and retail of medical equipment, maintenance of IT equipment and software related services.

The Group has three reportable segments including medical services, education and trading & retail business (note 21).

As at 30 September 2026 and 31 December 2025, the Group has investments in the following subsidiaries:

Name of subsidiaries	Country of Incorporation	Effective holding 2026	Effective holding 2025	Principal activities
Carecom IFM (Formerly, Al-Farabi Special Health Care Company Limited ("Farabi"))	Saudi Arabia	**70%**	70%	Healthcare service provider
Dr. Soliman Abdel Kader Fakeeh Information Technology Company (Formerly, Kameda Arabia Company Limited)	Saudi Arabia	**100%**	100%	IT equipment and software services
Dr. Soliman Abdel Kader Fakeeh Family Medicine Centers ("FMH")	Saudi Arabia	**90%**	90%	Healthcare service provider
Dr. Soliman Abdel Kader Fakeeh Medical Education Company Limited ("FMEC")	Saudi Arabia	**80%**	80%	Medical education service provider
Dr. Mazen Fakeeh Complementary Health Care Company Limited ("FCHC")	Saudi Arabia	**100%**	100%	Wholesale and retail of medical equipment
Al Toor Medical Services Company ("Al Toor")	Saudi Arabia	**51%**	51%	Healthcare service provider
Saudi Airlines Company for Medical Services ("SMS")	Saudi Arabia	**75%**	75%	Healthcare service provider

1. GENERAL (continued)

Name of subsidiaries	Country of Incorporation	Effective holding 2026	Effective holding 2025	Principal activities
Al-Faraj Pharmaceutical Medical Company ("Al-Faraj")	Saudi Arabia	**89.82%**	89.82%	Trading in pharmaceutical products
Advanced Horizon Contracting Company ("AHC")	Saudi Arabia	**100%**	100%	Construction and contracting
Golden Union Medical Company ("GUMC")	Saudi Arabia	**100%**	100%	Emergency medical services
Dr. Soliman Fakeeh Hospital Medical Company ("DSFH Riyadh")	Saudi Arabia	**68.36%**	68.36%	Healthcare service provider
White Lines Medical Company ("WLMC")	Saudi Arabia	**74.25%**	74.25%	Trading in pharmaceutical products
Fakeeh Vision Company Limited ("FVCL")	Saudi Arabia	**100%**	100%	Trading of spectacles and cosmetics
Dr. Soliman Abdel Kader Fakeeh Home Health Care Company ("FHHC")	Saudi Arabia	**100%**	100%	Home health care
Advance Lines Medical - ALM	Saudi Arabia	**74.25%**	74.25%	Trading in pharmaceutical products
Modern Algorithms Solutions for Information Technology Company	Saudi Arabia	**100%**	100%	Healthcare IT software services provider
Masar Dr. Sulaiman Fakeeh Hospital ("MDSFH")	Saudi Arabia	**100%**	100%	Healthcare service provider
Integrated Care Solution "ICS"	Saudi Arabia	**100%**	100%	Healthcare IT software services provider
Cyber Immunity Services Company ("CISC")	Saudi Arabia	**70%**	70%	IT equipment and software services
CareCom Company ("CC")	Saudi Arabia	**100%**	100%	Healthcare service provider
Dr. Sulaiman Fakeeh Hospital Alhamra Company (formerly, Dr. Mohammed Bin Rashed Al Fagih & Partners Co ("DMFH"))*	Saudi Arabia	**100%**	--	Healthcare service provider

* During the period, the Group acquired 100% of the share capital of Dr. Mohammed Bin Rashed Al Fagih & Partners Co. Following the acquisition, the company was renamed to Dr. Sulaiman Fakeeh Hospital Alhamra Company and became a wholly owned subsidiary of the Group. (Note 7).

2. BASIS OF PREPARATION

2.1 Basis of preparation

These condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standards 34 as issued by International Accounting Standards Board, (IAS) 34 "Interim Financial Reporting" that is endorsed in Kingdom of Saudi Arabia and other standards and pronouncements that are issued by the Saudi Organization for Chartered and Professional Accountants ("SOCPA") and should be read in conjunction with the Group's annual consolidated financial statements as at and for the year ended 31 December 2025 ("last annual Financial Statements").

These condensed consolidated interim financial statements do not include all of the information required for a complete set of annual consolidated financial statements prepared in accordance with IFRS Accounting Standards as endorsed in the Kingdom of Saudi Arabia. However, selected accounting policies and explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual consolidated financial statements. In addition, consolidated results for the interim period ended 30 September 2026, are not necessarily indicative of the results that may be expected for the financial year ending 31 December 2026.

2.2 Basis of measurement

These condensed consolidated interim financial statements have been prepared under the historical cost basis. Further, the condensed consolidated interim financial statements are prepared using the accrual basis of accounting and the going concern assumption.

2.3 Significant judgments, estimates and assumptions

The preparation of these condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses, accompanying disclosures, including disclosure of contingent liabilities. However, uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amount of the asset or liability in the future periods. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognised prospectively.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation of uncertainty were the same as those described in the last annual consolidated financial statements for the year ended 31 December 2025, except for the below:

Assessment of exercising significant influence over investee entity

During the period, the Group acquired an equity interest exceeding half of the voting rights of an investee. The determination of whether the Group has control, joint control or significant influence over an investee requires management to exercise significant judgement. Management assesses the existence of control by reference to its power over the investee, its exposure or rights to variable returns from its involvement, and its ability to use its power to affect those returns, in accordance with *IFRS 10 Consolidated Financial Statements*. Where the Group does not control an investee but has the power to participate in its financial and operating policy decisions, the investment is assessed as an associate over which the Group has significant influence and is accounted for using the equity method under *IAS 28 Investments in Associates and Joint Ventures*.

BASIS OF PREPARATION (Continued)

2.3 Significant judgments, estimates and assumptions (Continued)

Assessment of exercising significant influence over investee entity (Continued)
Notwithstanding a shareholding in excess of half of the voting rights, management concluded that the Group has significant influence, but not control, over the investee. In reaching this conclusion, management considered the governance and contractual arrangements in place, under which key operating and financial decisions require the consent of the other shareholder(s), such that the Group does not have the current ability to direct the relevant activities of the investee unilaterally.

Had management concluded that the Group controls the investee, the investment would have been consolidated with recognition of a non-controlling interest, rather than accounted for under the equity method. This judgement is therefore considered significant to the presentation of the consolidated financial statements (see note 8).

2.4 Functional and presentation currency

The Group's condensed consolidated interim financial statements are presented in Saudi Arabian Riyals, which is also the Parent Company's functional currency. For each entity, the Group determines the functional currency, and items included in the financial statements of each entity are measured using that functional currency.

3. NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS

a) New standards, interpretations and amendments adopted by the Group

Following amendments to IFRS Accounting Standards were effective on or after 1 January 2026, but they did not have a material effect on the condensed consolidated interim financial statements:

Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7

In May 2024, the IASB issued Amendments to IFRS 9 and IFRS 7, Amendments to the Classification and Measurement of Financial Instruments (the Amendments). The Amendments include:

- Clarifications of the requirements for recognition and derecognition of financial assets and financial liabilities. In particular, a financial liability is derecognised on the 'settlement date' and an accounting policy choice is introduced (if specific conditions are met) to derecognise financial liabilities settled using an electronic payment system before the settlement date
- Additional guidance on how the contractual cash flows for financial assets with environmental, social and corporate governance (ESG) and similar features should be assessed
- Clarifications on what constitute 'non-recourse features' and what are the characteristics of contractually linked instruments
- The introduction of disclosures for financial instruments with contingent features and additional disclosure requirements for equity instruments classified at fair value through other comprehensive income (OCI)

The amendments had no impact on the Group's condensed consolidated interim financial statements.

3. NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS (Continued)

Annual Improvements to IFRS accounting Standards – Volume 11
In July 2024, the IASB issued nine narrow scope amendments as part of its periodic maintenance of IFRS accounting standards. The amendments include clarifications, simplifications, corrections or changes to improve consistency in IFRS 1 First-time Adoption of International Financial Reporting Standards, IFRS 7 Financial instruments: Disclosure and its accompanying Guidance on implementing IFRS 7, IFRS 9 Financial Instruments, IFRS 10 Consolidated Financial Statements and IAS 7 Statements of Cash Flows.

The amendments had no impact on the Group's condensed consolidated interim financial statements.

Contracts Referencing Nature -dependent Electricity – Amendments to IFRS 9 and IFRS 7
In December 2024, the IASB issued Amendments to IFRS 9 and IFRS 7 – Contracts Referencing Nature dependent Electricity. The amendments apply only to contracts that reference nature-dependent electricity, and they:

- Clarify the application of the 'own-use' requirements for in-scope contracts
- Amend the designation requirements for a hedged item in a cash flow hedging relationship for in -scope contracts
- Add new disclosure requirements to enable investors to understand the effect of these contracts on a company's financial performance and cash flows

The amendments had no impact on the Group's condensed consolidated interim financial statements.

b) Standards issued but not yet effective

Expected impact of the initial application of IFRS 18 ("Presentation and Disclosure in Financial Statements")

In April 2024, the International Accounting Standards Board ("IASB") issued IFRS 18 Presentation and Disclosure in Financial Statements, which replaces IAS 1 Presentation of Financial Statements and becomes effective for annual reporting periods beginning on or after 1 January 2027. The new standard introduces new requirements and updates to the statement of profit or loss, with the main objective of improving comparability in the statement of profit or loss and enhancing transparency over management-defined performance measures.

The key new concepts introduced by IFRS 18 include:

- A revised structure of the statement of profit or loss, requiring classification of income and expenses into 5 defined categories based on the entity's main business activities and presentation of mandatory subtotals;
- Enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes in general; and
- Required disclosures in the financial statements for certain profit or loss performance measures that are reported outside an entity's financial statements (that is, management-defined performance measures).

The Group is in the process of assessing the estimated impact that the initial application of IFRS 18 will have on its financial statements.

3. NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS (Continued)

b) Standards issued but not yet effective (continued)

Expected impact of the initial application of IFRS 18 ("Presentation and Disclosure in Financial Statements") (continued)

1- Structure of the Statement of Profit or Loss

The standard is expected to result in changes to the presentation of certain line items and subtotals in the statement of profit or loss namely operating, investing, financing, zakat/income tax and discontinued operations. This classification depends on the main business activities of the entity. The Group does not have a specified main business activity as defined in IFRS 18.

Based on the Group preliminary assessment and the nature of its business activities, performed to date at a high level, the Group expects changes to the current structure of Statement of Profit or Loss to result in:

- The Group continues to present operating profit line item however, operating profit will be affected by presentation/placement of certain items within and outside the operating profit such as bank commissions currently presented within finance cost will be classified within general and administrative expenses in the operating category and will reduce the operating profit. Further, finance cost on the Group's employees' end of service benefit obligation currently presented within salaries and related benefits will be classified and presented within the financing category and will increase the operating profit.
- Finance income from investment in Sukuk and short-term deposits currently presented within finance income will be classified in the new investing category of IFRS 18. There would be an additional subtotal 'Profit before financing and Zakat' after investing category.
- The Group's new investing category would include finance income from investment in Sukuk and short-term deposits and share of results from investment in associate.
- The Group's new financing category would include finance cost on loans, lease liabilities and Group's employees end of service benefit obligation.
- The Group expects the Zakat to be presented in income tax category of IFRS 18 hence, there is no change from existing presentation under IAS 1.

2- Aggregation and Disaggregation

The new aggregation and disaggregation requirements will lead into changes to present the most useful structured summary. The Group is assessing how items are aggregated and disaggregated in the primary financial statements and the notes on the basis of similar and dissimilar characteristics.

Certain statement of financial position and profit or loss line items description and aggregations may change to provide useful structured summaries and disclose additional material information in the notes.

The Group identified that goodwill previously presented within intangible assets and goodwill will be presented within a separate goodwill line item in the non-current asset category.

The Group is performing a detailed assessment to determine the appropriate classification of items.

3. NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS (Continued)

b) Standards issued but not yet effective (continued)

Expected impact of the initial application of IFRS 18 ("Presentation and Disclosure in Financial Statements") (continued)

3- Management-defined performance measures (MPMs)

Management-defined Performance Measures (MPMs) is a subtotal of income and expenses that entity uses in public communication outside the financial statements that communicates management's view of an aspect of the financial performance of the entity as a whole. Where applicable, these measures may require quantitative reconciliation to IFRS-defined subtotals together with expanded explanatory disclosures.

The Group is in the process of identifying which performance measures communicated to investors, analysts and other stakeholders (including adjusted earnings measures, underlying profit measures and certain operating performance metrics) will meet the definition of an MPM under IFRS 18 and accordingly, the Group will comply with the IFRS 18 disclosure requirements in this regard.

4- Consequential amendments

The Group is also evaluating the consequential amendments arising from IFRS 18, including amendments to IAS 7 Statement of Cash Flows and IAS 34 Interim Financial Reporting.

The Group currently uses profit before zakat as a starting point of the reconciliation to cash flows from operating activities which will be changed to operating profit. Certain adjusting items included in the reconciliation will change as a result of the new starting point.

The consequential amendments also provide specific guidance on the classification of interest and dividend cash flows. The Group will classify cash flows from interest paid as financing activities rather than operating activities under IFRS 18. Cash flows from interest received and dividends paid will continue to be classified as investing and financing activities, respectively.

The Group assessment remains ongoing and further refinements to the expected impact may arise as implementation activities progress and additional industry and regulatory guidance becomes available.

4. MATERIAL ACCOUNTING POLICIES

The accounting policies applied in these condensed consolidated interim financial statements are the same as those applied in the Group's annual consolidated financial statements as at and for the year ended 31 December 2025, except for the adoption of new standards effective as of 1 January 2026 (as detailed in note 3 (a)) and the following accounting policy in relation to investment in associate. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.

Investment in associate
An associate is an entity over which the Group has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but is not control or joint control over those policies.

4. MATERIAL ACCOUNTING POLICIES

Investment in associate (Continued)

The considerations made in determining significant influence are similar to those necessary to determine control over subsidiaries. The Group's investment in its associate is accounted for using the equity method. The aggregate of the Group's share of profit or loss of an associate is shown on the face of the statement of profit or loss outside operating profit and represents profit or loss after zakat and non-controlling interests in the subsidiaries of the associate.

Under the equity method, the investment in an associate is initially recognised at cost. The carrying amount of the investment is adjusted to recognise changes in the Group's share of net assets of the associate since the acquisition date. Goodwill relating to the associate is included in the carrying amount of the investment and is not tested for impairment separately.

The statement of profit or loss reflects the Group's share of the results of operations of the associate. Any change in OCI of those investees is presented as part of the Group's OCI. In addition, when there has been a change recognised directly in the equity of the associate, the Group recognises its share of any changes, when applicable, in the statement of changes in equity.

The financial statements of the associate are prepared for the same reporting period as the Group. When necessary, adjustments are made to bring the accounting policies in line with those of the Group.

After application of the equity method, the Group determines whether it is necessary to recognise an impairment loss on its investment in its associate. At each reporting date, the Group determines whether there is objective evidence that the investment in the associate is impaired. If there is such evidence, the Group calculates the amount of impairment as the difference between the recoverable amount of the associate and its carrying value, and then recognises the loss

Upon loss of significant influence over the associate, the Group measures and recognises any retained investment at its fair value. Any difference between the carrying amount of the associate upon loss of significant influence and the fair value of the retained investment and proceeds from disposal is recognised in profit or loss.

5. PROPERTY AND EQUIPMENT

5.1 Reconciliation of carrying amounts:

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Carrying amount at beginning of the period / year	**2,498,755**	2,095,843
Additions during the period / year	**226,426**	520,329
Disposals during the period / year	**(4,547)**	(3,357)
Transfer to intangibles during the period / year	**(1,817)**	(2,503)
Acquisition of a subsidiary (Note 7)	**1,033,575**	--
Depreciation charge for the period / year	**(108,313)**	(111,557)
Carrying amount at the end of the period / year	**3,644,079**	2,498,755

5.2 Category-wise carrying amounts are as follows:

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Land	**652,017**	387,521
Buildings and leasehold improvements	**1,761,033**	998,615
Medical and support equipment	**589,528**	479,068
Furniture and fixtures	**57,736**	35,323
Motor vehicles	**15,285**	17,651
Office equipment	**71,788**	24,034
Computers	**59,824**	50,528
Capital work-in-progress (note 5.3)	**436,868**	506,015
	3,644,079	2,498,755

5.3 Capital work-in-progress mainly represents the construction work being carried out for the Group's expansion projects and upgrading the existing infrastructure and facilities.

5.4 During the period ended 30 September 2026, an amount of SR 25.7 million (31 December 2025: SR 29.1 million) was capitalized as borrowing cost.

6. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

6.1 Right-of-use assets

a) Reconciliation of carrying amounts

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Cost:		
Balance at the beginning of the period / year	**738,866**	708,076
Additions during the period / year	**138,958**	67,490
Modifications during the period / year	**2,363**	(22,639)
Terminations for the period / year	**(20,873)**	(14,061)
Acquisition of a subsidiary (Note 7)	**10,178**	--
Balance at the end of the period / year	**869,492**	738,866

6 RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (continued)

6.1 Right-of-use assets (continued)

a) Reconciliation of carrying amounts (continued)

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Accumulated depreciation:		
Balance at the beginning of the period / year	**246,619**	202,738
Depreciation charge for the period / year	**51,901**	62,690
Modifications	**--**	(10,651)
Terminations for the period / year	**(20,779)**	(8,158)
Balance at the end of the period / year	**277,741**	246,619
Carrying amounts at the end of the period / year	**591,751**	492,247

6.2 Lease liabilities

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Balance at the beginning of the period / year	**544,824**	541,394
Additions during the period / year	**138,958**	67,490
Interest expenses for the period / year (Note 17.a)	**18,550**	23,109
Interest capitalized for the period / year	**10,144**	9,041
Modifications	**2,363**	(14,460)
Terminations for the period / year	**(100)**	(6,178)
Interest paid during the period / year	**(28,694)**	(32,150)
Payments during the period / year	**(42,431)**	(43,422)
Acquisition of a subsidiary (Note 7)	**10,853**	--
Balance at the end of the period / year	**654,467**	544,824

Lease liabilities are presented in the condensed consolidated interim statement of financial position as follows:

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Non-current portion of lease liabilities	**573,567**	481,162
Current portion of lease liabilities	**80,900**	63,662
	654,467	544,824

7 GOODWILL AND INTANGIBLE ASSETS

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Goodwill on acquisition of subsidiaries DSFH Riyadh and SMS (Note a)	**488,816**	488,816
Provisional goodwill on acquisition of DMFH (Note b)	**1,030,655**	**--**
Medical licenses	**16,241**	18,243
Customer relationships	**15,027**	17,247
Computer software	**34,927**	12,462
Software under development	**1,619**	10,800
	1,587,285	547,568

a. The Group performs its annual impairment test in December or when circumstances indicate that the carrying value may be impaired whichever is earlier. The Group's impairment test for goodwill is based on value-in-use calculations. The key assumptions used to determine the recoverable amount for the different cash generating units were disclosed in the annual consolidated financial statements for the year ended 31 December 2025. There were no significant changes in key assumptions and sensitivity information disclosed in the annual consolidated financial statements for the year ended 31 December 2025.

b. The Parent Company acquired 100% of shareholding in Dr. Mohammed Bin Rashed Al Fagih & Partners Co ("DMFH") for a total cash consideration of SR 1,595.6 million. The acquisition date is 20 July 2026. Of the total cash consideration amount, SR 100 million is placed in an escrow account, for a period of six months from acquisition date, to indemnify the Group for any breaches or issues that relate to the pre-acquisition period.

The acquisition was accounted for using the acquisition method of accounting. The purchase consideration in excess of the provisional fair value of the net assets acquired amounted to SR 1,030.66 million, was recorded as provisional goodwill based on the provisional assessment of the fair value of DMFH net assets by the management. The purchase price allocation is expected to be completed within 12 months of the acquisition date (i.e., the measurement period). The provisional goodwill is calculated as follows:

Description	**Thousands of SR**
Purchase consideration paid	**1,595,625**
Less: Provisional fair values of net assets acquired	**(564,970)**
Provisional goodwill	**1,030,655**

8 INVESTMENT IN ASSOCIATE

On 22 June 2026, the Group acquired a 50.01% equity interest in Diagnostic Elite Company Limited, a limited liability company incorporated in the Kingdom of Saudi Arabia, for total consideration of SR 55.3 million paid in cash. Subsequent to the acquisition, the group contributed additional capital of SR 14.65 million. The Group has assessed that it exercises significant influence over Diagnostic Elite Company Limited and has classified the investment as an associate, accounted for using the equity method in accordance with IAS 28.

	30 September 2026 (Unaudited)
Cost of acquisition	**55,350**
Additional capital contribution	**14,650**
Share of profits	**82**
Carrying amount	**70,082**

9 OTHER LONG-TERM RECEIVABLES

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Non-current portion of receivables under DAAM scholarship Program	**135,950**	144,748

10 ACCOUNTS RECEIVABLES

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Accounts receivables	**1,344,020**	1,092,796
Accounts receivables - related parties (note 19)	**37,076**	23,351
	1,381,096	1,116,147
Less: allowance for impairment losses (10.1)	**(152,722)**	(141,169)
	1,228,374	974,978

10.1 The movement of allowance for impairment losses is as follows:

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Balance at beginning of the period / year	**141,169**	131,079
Provision for impairment losses during the period / year	**22,375**	24,420
Written off during the period / year	**(10,822)**	(14,330)
Balance at end of the period / year	**152,722**	141,169

10.2 The contract asset primarily relates to operating project contract with customers.

11 CASH AND CASH EQUIVALENTS

Cash and cash equivalents include cash in hand, bank balances and short term deposits with original maturities of less than 3 months.

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Cash in hand	**5,661**	3,992
Cash at banks - current accounts	**206,511**	167,170
Short-term deposits	**224,200**	268,000
	436,372	439,162

At each reporting date, all bank balances are assessed to have low credit risk as they are held with reputable and high credit rating domestic banking institutions and there has been no history of default with any of the Group's bank balances. Therefore, the probability of default based on forward-looking factors and any loss given defaults are considered to be negligible.

Short-term deposits are made at the available short-term deposit rates for varying periods of between one day to three months, depending on the immediate cash requirements of the Group.

12 SHARE CAPITAL

As at 30 September 2026, the share capital of the Parent Company comprised of 232 million shares at a nominal value of SR 1 per share (31 December 2025: 232 million shares).

	No. of Shares	**Amount**
Dr. Mazen Soliman Abdel Kader Fakeeh	71,649	71,649
Mr. Ammar Sulayman A. Faqih	71,649	71,649
Dr. Manal Soliman Abdel Kader Fakeeh	35,824	35,824
Fakeeh Real Estate Company Limited (A Saudi Limited Liability Company)	20	20
Al Solimania United Company Limited (A Saudi Limited Liability Company)	20	20
Employee Share Ownership Plan (note 12.a)	2,000	2,000
Free Float	50,838	50,838
	232,000	**232,000**

a. Employee Share Ownership Program

On 23 November 2023 (corresponding to 9 Jumada Al Awwal 1445H), the Parent Company's Extraordinary General Assembly approved the issuance of 2 million New Shares through the capitalization of SR 2 million of retained earnings and retain them as treasury shares. These treasury shares will be allocated to the Employee Share Program for the Group in accordance with the applicable terms and conditions. The Employee Share Program will be set-up after the required approvals, to attract and retain outstanding employees. The Extraordinary General Assembly authorized the Board of Directors to implement the Employee Share Program, subject to the related laws.

12 SHARE CAPITAL (continued)

a. Employee Share Ownership Program (Continued)

During the first quarter of 2025, the Long-Term Incentive Plan "LTIP" detailed policy was approved by the Board of Directors and was ratified by the EGM in the 1st quarter of 2026. This LTIP cycle will run for 3 years starting from 1st January 2025 and despite the existence of a cliff, the fair value of award will be recognized as Non-Cash Share based Payment during the three years period proportionately and on a quarterly basis.

The LTIP is solely settled through Shares. The number of shares allocated to each employee is communicated at the Grant date to the Employees, however, the actual number of shares at the end of the 3-year period will vary based on the actual vesting conditions as such the LTIP falls within the "'Equity-settled share-based payment transactions".

b. During the year 2025, the general assembly approved the distribution of cash dividends amounting to SAR 69 million representing a dividend of SAR 0.30 for each issued share excluding shares under the employee share ownership program.

c. During the year 2026, the general assembly approved the distribution of cash dividends amounting to SAR 75.9 million representing a dividend of SAR 0.33 for each issued share excluding shares under the employee share ownership program.

13 LOANS AND BORROWINGS

The Group is financed through facilities from local banks which include both long-term and short-term loans. These facilities are Sharia compliant and are subject to Saudi Arabia interbank Offered Rate "SIBOR" plus a margin. Certain loans are subject to certain bank covenants which are fully compliant at the reporting date.

Movement summary of the loans and borrowings during the period / year is as follows:

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Balance at beginning of the period / year	**631,543**	536,500
Proceeds during the period / year	**2,589,220**	748,111
Payments made during the period / year	**(804,690)**	(653,068)
Acquisition of a subsidiary (note 7)	**561,109**	--
Balance at end of the period / year	**2,977,182**	631,543

Long-Term Loans	**30 September 2026 (Unaudited)**	31 December 2025 (Audited)
Balance at beginning of the period / year	**334,000**	321,500
Proceeds during the period / year	**1,802,000**	13,500
Payments made during the period / year	**(328,933)**	(1,000)
Acquisition of a subsidiary (note 7)	**561,109**	--
Balance at end of the period / year	**2,368,176**	334,000

Out of the above long term loans, an amount of SR 43.7 million is due within one year from the reporting date and has been presented under "current liabilities".

13 LOANS AND BORROWINGS (CONTINUED)

Short-Term Loans	**30 September 2026 (Unaudited)**	31 December 2025 (Audited)
Balance at beginning of the period / year	**297,543**	215,000
Proceeds during the period / year	**787,220**	734,611
Payments made during the period / year	**(475,757)**	(652,068)
Balance at end of the period / year	**609,006**	297,543

The Group has long term facilities of SAR 3,475 million as at 30 September 2026 (31 December 2025: 1,400 million) from commercial banks and the Ministry of Finance for new investment and capital projects, out of which the Group has utilized SAR 2,368.2 million as at 30 September 2026 (31 December 2025: 334 million). The Loans carry interest at prevailing market interest rates

Through the business combination (note 7), the Group assumed loans and borrowings of DMFH amounting to SR 561.1 million. These comprise a long-term Murabaha facility of SR 236.1 million from the Ministry of Finance, obtained to finance the construction of the DMFH hospital, with a balance of 230.2 million as at 30 September 2026, which carries an annual charge of 2.1%; and long-term and short-term facilities from local banks of SR 325 million, which carry commission at the SIBOR plus a margin. The facilities are secured by a mortgage over DMFH's land and buildings.

In total the Group has short term facilities of SAR 1,095 million as at 30 September 2026 (31 December 2025: 1,000 million) from commercial banks out of which the Group has utilized SAR 609.0 million as at 30 September 2026 (31 December 2025: 297.5 million). The Loans carry interest at prevailing market interest rates.

14 ZAKAT

a) Charge for the period:

Zakat included in the condensed consolidated interim statement of profit or loss and other comprehensive income are comprised of the following:

	30 September 2026 (Unaudited)	30 September 2025 (Unaudited)
Charge for the period	**18,133**	23,914

The movement in the accrual for Zakat is as follows:

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Balance at beginning of the period / year	**30,291**	25,484
Charge for current period / year	**18,133**	32,335
Payments during the period / year	**(31,946)**	(27,528)
Acquisition of a subsidiary (note 7)	**1,294**	--
Balance at end of the period / year	**17,772**	30,291

14 ZAKAT (CONTINUED)

b) Status of assessments

All the below companies have filed their Zakat return for the years up to 31 December 2025 and received unrestricted Zakat certificates for the same periods.

Company name	Financial years open for Zakat assessment
Dr. Soliman Abdel Kader Fakeeh Hospital Company	2021 – 2025
Al-Farabi Special Health Care Company Limited	2021 – 2025
Dr. Soliman Kader Fakeeh Information Technology Company	2021 – 2025
Dr. Soliman Abdel Kader Fakeeh Family Medicine Centers	2021 – 2025
Dr. Soliman Abdel Kader Fakeeh Medical Education Company Limited	2021 – 2025
Dr. Mazen Fakeeh Complementary Health Care Company Limited	2021 – 2025
Al Toor Medical Services Company	2022 – 2025
Saudi Airlines Company for Medical Services	2021 – 2025
Al-Faraj Pharmaceutical Medical Company	2021 – 2025
Advanced Horizon Contracting Company	2021 – 2025
Golden Union Medical Company	2021 – 2025
Dr. Soliman Fakeeh Hospital Medical Company	2021 – 2025
Dr. Soliman Abdel Kader Fakeeh Home Health Care Company	2023 – 2025
White Lines Medical Company	2023 – 2025
Fakeeh Vision	2023 – 2025
Masar Dr. Sulaiman Fakeeh Hospital	2025
Integrated Care Solutions	2025
Modern Algorithms Solutions for Information Technology Company	2025
Advance Lines Medical Company	2025
Dr. Sulaiman Fakeeh Hospital Alhamra Company (formerly, Dr. Mohammed Bin Rashed Al Fagih & Partners Co (“DMFH”))	2021 – 2025

15 REVENUE

Disaggregation of revenue from contracts with customers

In the following table, revenue from contracts with customers is disaggregated by major service lines and timing of revenue recognition, all revenue is primarily generated in the Kingdom of Saudi Arabia:

	For the nine-month period ended 30 September 2026 (Unaudited)	For the nine-month period ended 30 September 2025 (Unaudited)
Revenue from Health care operations	**2,185,270**	2,098,325
Revenue from Medical related services	**85,877**	92,878
Revenue from Education services	**95,507**	88,673
Revenue from IT and other services	**87,665**	11,245
	2,454,319	2,291,121

	For the nine-month period ended 30 September 2026 (Unaudited)	For the nine-month period ended 30 September 2025 (Unaudited)
Timing of revenue recognition		
Point in time	**1,405,210**	1,450,086
Over time	**1,049,109**	841,035
Revenue from contracts with customers	**2,454,319**	2,291,121

16 GENERAL AND ADMINISTRATIVE EXPENSES

	For the nine-month period ended 30 September 2026 (Unaudited)	For the nine-month period ended 30 September 2025 (Unaudited)
General and administrative expenses	**256,119**	229,625
Non-Cash Share based Payment	**3,507**	5,668
	259,626	235,293

17 FINANCE COST AND INCOME

a. Finance Costs

	For the nine-month period ended 30 September 2026 (Unaudited)	For the nine-month period ended 30 September 2025 (Unaudited)
Interest expenses – loan	**50,570**	17,348
Interest expenses – lease liabilities (Note 6.2)	**18,550**	16,692
	69,120	34,040

b. Finance Income

Finance income is recognized using effective interest method. Time deposits are placed with financial institutions in the Kingdom of Saudi Arabia; these deposits are sharia compliant.

	For the nine-month period ended 30 September 2026 (Unaudited)	For the nine-month period ended 30 September 2025 (Unaudited)
Income from deposits and government Sukuk	**20,644**	17,863

18 EARNINGS PER SHARE

Basic earnings per share (EPS) is calculated by dividing profit for the period attributable to ordinary shareholders of the Parent Company by the weighted average number of ordinary shares in issue outstanding during the period.

	For the nine-month period ended 30 September 2026 (Unaudited)	For the nine-month period ended 30 September 2025 (Unaudited)
Profit for the period attributable to ordinary shareholders of the Parent Company	**135,090**	225,966
Weighted average number of ordinary shares in issue	**230,000**	230,000
Basic and diluted earnings per share	**0.59**	0.98

19 RELATED PARTY TRANSACTIONS AND BALANCES

The Group, in the normal course of business, enters into transactions with other entities that fall within the definition of a related party contained in International Accounting Standard 24 as endorsed in KSA. Related parties comprise of the shareholders of the Group, being Parent Company, its subsidiaries and associates, and other companies with common directorship with significant influence on other companies and key management personnel. Transactions with related parties arise mainly from goods/services received and various business arrangements undertaken at management approved contractual terms.

19 RELATED PARTY TRANSACTIONS AND BALANCES (continued)

Transactions with key management personnel

Key management personnel compensation

a) Key management personnel remuneration and compensation comprised of the following:

	For the nine-month period ended 30 September 2026 (Unaudited)	For the nine-month period ended 30 September 2025 (Unaudited)
Short-term employee benefits	**21,057**	18,963
Board of Directors' and related committee remuneration	**2,854**	1,089
Post-employment benefits	**916**	822
	24,827	20,874

b) Related party transactions

Related party	Nature of transactions	Amount of transactions	
		30 September 2026 (Unaudited)	30 September 2025 (Unaudited)
Shareholder	Lease rental payments	**24,786**	24,671
Shareholder	Payments made on behalf of the related party	**1,377**	1,162
Shareholder and associate	Consideration for acquisition of shares in Diagnostic Elite Company (note 8)	**70,000**	--
Non - controlling Shareholder	Revenue	**24,918**	26,645
Non - controlling Shareholder	Lease rental payments	**17,838**	23,089
Non - controlling Shareholder	Purchases	**611**	--
Entities under common ownership of the Group's controlling shareholder	Royalty Charges	**2,988**	1,800
Entities under common ownership of the Group's controlling shareholder	Revenue	**2,034**	3,523
Entities under common ownership of the Group's controlling shareholder	SLA Charges	**1,688**	900
Entities under common ownership of the Group's controlling shareholder	Payments made on behalf of the related party	**1,005**	713
Entities under common ownership of the Group's controlling shareholder	Lease rental payments	**307**	558
Associate	purchases	**2,427**	3,540

19 RELATED PARTY TRANSACTIONS AND BALANCES (continued)

c) Related party closing balances

Name	Balance as of	
	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Due from related parties – (Accounts receivables and prepayments and other current assets)		
Non - controlling Shareholder	**36,251**	25,261
Entities under common ownership of the Group's controlling shareholder	**14,842**	14,063
Shareholder	**4,909**	3,532
Others	**92**	80
	56,094	42,936

	30 September 2026 (Unaudited)	31 December 2025 (Audited)
Due to related parties – (Accounts payables, Accrued and other current liabilities)		
Associate	**509**	1,434
Non - controlling Shareholder	**--**	--
	509	1,434

20 COMMITMENTS AND CONTINGENCIES

As at 30 September 2026 the Group has:

- Outstanding letters of guarantee amounting to SR 30.1 million (31 December 2025: SR 38.7 million).
- Outstanding letters of credit amounting to SR 15.2 million (31 December 2025: SR 4.9 million).
- Commitments for capital work in progress of SR 122.3 million (31 December 2025: SR 163 million) mainly relating to investments and construction, renovation and upgradation of buildings.

As at 30 September 2026, there are no significant litigations and claims against the Group.

21 BUSINESS SEGMENTS

As the operations of the Group are conducted in the Kingdom of Saudi Arabia, accordingly, for management purposes, the Group is organized into business units based on its products and services and has three reportable segments. Operating segments is determined based on the Group's internal reporting to the Chief Operating Decision Maker ("CODM"). The CODM has been determined to be the President as he is primarily responsible for the allocation of resources to segments and the assessment of the performance of each of the segments. The CODM uses underlying income as reviewed at monthly Executive Committee and Performance meetings as the key measure of the segments' results as it reflects the segments' performance for the period under evaluation. Revenue and segment profit is a consistent measure within the Group. The identified key segments are medical services, education, trading and retail.

Information regarding the results of each reportable segment is included below. Performance is measured based on segment revenues, as included in the internal management reports that are reviewed by the top management. The following table presents segment information (assets, liabilities, revenue and net income) for each of the business segments as at and for the nine-month period ended 30 September:

	Reportable Segments				
30 September 2026 (Unaudited)	**Medical services**	**Education**	**Trading, Retail & Others**	**Un-Allocated**	**Total**
Revenues	2,231,278	96,708	379,970	--	2,707,956
Inter-segment revenue eliminations	(19,867)	(1,201)	(232,569)	--	(253,637)
Segment revenue	**2,211,411**	**95,507**	**147,401**	**--**	**2,454,319**
Direct costs	(1,794,144)	(53,131)	(286,647)	--	(2,133,922)
Inter-segment direct costs	19,867	--	176,504	--	196,371
Segment cost	**(1,774,277)**	**(53,131)**	**(110,143)**	**--**	**(1,937,551)**
Segment gross profit	**437,134**	**42,376**	**37,258**	**--**	**516,768**
Operating expenses	-	-	-	(320,760)	(320,760)
Impairment loss on accounts receivables	(17,267)	(1,393)	(3,715)	-	(22,375)
Other income	-	-	-	11,130	11,130
Operating profit	**419,867**	**40,983**	**33,543**	**(309,630)**	**184,763**
Finance cost	-	-	-	(69,120)	(69,120)
Finance income	-	-	-	20,644	20,644
Zakat	-	-	-	(18,133)	(18,133)
Share of profit from investment in associate	-	-	-	82	82
Profit for the period	**419,867**	**40,983**	**33,543**	**(376,157)**	**118,236**
30 September 2026 (Unaudited)					
Total assets	**7,968,811**	**279,146**	**231,335**	**-**	**8,479,292**
Total liabilities	**4,475,588**	**135,462**	**170,405**	**49,188**	**4,830,643**

21 BUSINESS SEGMENTS (continued)

	Reportable Segments				
30 September 2025 (Unaudited)	**Medical services**	**Education**	**Trading, Retail & Others**	**Un-Allocated**	**Total**
Revenues	2,126,534	89,640	325,614	--	2,541,788
Inter-segment revenue eliminations	(15,026)	(967)	(234,674)	--	(250,667)
Segment revenue	**2,111,508**	**88,673**	**90,940**	**--**	**2,291,121**
Direct costs	(1,625,626)	(45,402)	(284,697)	--	(1,955,725)
Inter-segment direct costs	15,026	--	183,576	--	198,602
Segment cost	**(1,610,600)**	**(45,402)**	**(101,121)**	**--**	**(1,757,123)**
Segment gross profit	**500,908**	**43,271**	**(10,181)**	**--**	**533,998**
Operating expenses	--	--	--	(292,939)	(292,939)
Impairment loss on accounts receivables	(13,510)	(1,260)	(4,453)	--	(19,223)
Other income	--	--	--	10,882	10,882
Operating profit	**487,398**	**42,011**	**(14,634)**	**(282,057)**	**232,718**
Finance cost	--	--	--	(34,040)	(34,040)
Finance Income	--	--	--	17,863	17,863
Zakat	--	--	--	(23,914)	(23,914)
Profit for the period	**487,398**	**42,011**	**(14,634)**	**(322,148)**	**192,627**
31 December 2025 (Audited)					
Total assets	**5,429,658**	**199,293**	**199,726**	**--**	**5,828,677**
Total liabilities	**1,706,935**	**108,749**	**394,997**	**36,610**	**2,247,291**

The Group's top management reviews internal management reports of each strategic business unit at least quarterly. Segment results that are reported to the top management include items directly attributable to a segment as well as those that can be allocated on a reasonable basis.

22 FAIR VALUE OF FINANCIAL ASSETS AND FINANCIAL LIABILITIES

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction takes place either:

- In the accessible principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous accessible market for the asset or liability
- Fair value information of the Group's financial instruments is analyzed below:

22 FAIR VALUE OF FINANCIAL ASSETS AND FINANCIAL LIABILITIES (continued)

The Group uses the following hierarchy for determining and disclosing the fair value of financial instruments:

Level 1: quoted prices in active markets for the same or identical instrument that an entity can access at the measurement date;

Level 2: quoted prices inactive markets for similar assets and liabilities or valuation techniques for which all significant inputs are based on observable market data; and

Level 3: valuation techniques for which any significant input is not based on observable market data.

There were no transfers between level 1 and level 3 during the nine-month period 30 September 2026 (31 December 2025: nil). There were no financial assets or financial liabilities classified under level 2 (31 December 2025: nil).

There were no changes in valuation techniques during the period. As at 30 September 2026, the financial assets of the Group are comprised of financial assets at amortized cost, prepayments and other current assets, accounts receivables, contract assets and cash and cash equivalents which are recorded at amortized cost and their carrying values approximate their fair values. The Group's financial liabilities include long-term and short-term loans, accounts payable, accruals and other liabilities.

23 SUBSEQUENT EVENTS

There have been no significant subsequent events since the balance sheet date that require disclosure or adjustments in these financial statements.

24 GEOPOLITICAL DEVELOPMENTS

During the current period, geopolitical tensions in parts of the Middle East have increased. Public communications from government and regulatory authorities have continued to emphasize the resilience of the economy and the continuation of business operations across key sectors, supported by established business continuity and risk management frameworks.

Fakeeh Care Group has been monitoring the potential implications of these geopolitical developments on its operations, financial position and financial performance. Based on the information available as at the date of these consolidated financial statements, management has not identified any material impact on the Group's operations for the current period, although the extent of any effect on future periods remains uncertain. Accordingly, it is not currently practicable to reliably estimate the full financial effect, if any, of these developments on future periods.

Management has also considered the impact of these matters on the Group's ability to continue as a going concern and has concluded that the going concern basis of preparation remains appropriate.

25 DATE OF AUTHORIZATION FOR ISSUE

The condensed consolidated interim financial statements were approved and authorized for issue by the Board of Directors of Parent Company on 4 November 2026, corresponding to 24 Jumada Al Ula 1448H.

Mr. Ammar Faqih	Dr. Mazen Fakeeh	Mr. Taha Bin Shaukat
Chairman Board of Directors	President	Group Chief Financial Officer